Kite submits BLA for CAR T in non-Hodgkin lymphomas
September 4, 2020 -- Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies. Read More
Magenta to explore targeted gene editing to cure HIV
September 3, 2020 -- Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure HIV. Read More
Gyros launches new product to support cell & gene therapy manufacturing
September 2, 2020 -- Gyros Protein Technologies introduced a new product for adeno-associated virus vector titer determination. Read More
Unum Therapeutics transfers BOXR cell-based therapy to Sotio
September 1, 2020 -- Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio. Read More
Cartesian begins trial of RNA-based cell therapy for COVID-19
September 1, 2020 -- Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including ARDS caused by COVID-19. Read More
Molecular barcoding of DNA identifies rare mutations in stem cells
August 27, 2020 -- Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24. Read More
Carisma, NYU Langone to develop Vpx lentiviral vector
August 25, 2020 -- Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications. Read More
Expression Therapeutics develops stem cell lentiviral gene therapy
August 24, 2020 -- Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3. Read More
IsoPlexis, Lonza partner on cell therapy manufacturing
August 20, 2020 -- IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing. Read More
Fujifilm Diosynth breaks ground on biologics facility
August 19, 2020 -- Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter